Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a PK/PD study of PXL770 in male subjects with adrenomyeloneuropathy
2021-006223-18Phase 2Terminated
- Sponsor
- Poxel SA
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of PXL770 in adrenomyeloneuropathy (AMN) (2 arms), sponsored by Poxel SA. Primary endpoints: Primary plasma PK parameters for 500 mg OD and Primary plasma PK parameters for 250 mg BID. Started Jan 2022; status: terminated.
02
Drugs
PXL770
03
Conditions
adrenomyeloneuropathy (AMN)
Beyond the preview
Go deeper on 2021-006223-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006223-18.